 

Active Ingredient: Aminocaproic acid 

 

Dosage Form; Route: Tablet; oral 

 

Recommended Studies: Two studies 

 

1. Type of study: Fasting 


Design: Single-dose, two-way crossover in vivo 

Strength: 1000 mg 

Subjects: Healthy males and nonpregnant females, general population 

Additional comments: None 

 


2. Type of study: Fed 


Design: Single-dose, two-way crossover in vivo 

Strength: 1000 mg 

Subjects: Healthy males and nonpregnant females, general population 

Additional comments: None 

 


Analytes to measure (in appropriate biological fluid): Aminocaproic acid in plasma 

Bioequivalence based on (90% CI): Aminocaproic acid 

Waiver request of in vivo testing: 500 mg strength based on (i) acceptable bioequivalence 
studies on the 1000 mg strength, (ii) acceptable in vitro dissolution testing of all strengths, and 
(iii) proportional similarity of the formulations across all strengths 

Dissolution test method and sampling times: The dissolution information for this drug 
product can be found on the FDA-Recommended Dissolution Methods Web site, available to the 
public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. 
Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and 
reference products. Specifications will be determined upon review of the abbreviated new drug 
application (ANDA). 


